Supernus Pharmaceuticals (SUPN) Cash & Current Investments (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Cash & Current Investments data on file, last reported at $384.2 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $384.2 million, down 17.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $384.2 million (down 17.12% YoY), and the FY2025 annual result was $308.7 million, down 31.95% from the prior year.
• Cash & Current Investments rose to $384.2 million in Q1 2026 per SUPN's latest filing, from $308.7 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $522.6 million in Q2 2025 and troughed at $151.7 million in Q2 2023.
• A 5-year average of $342.6 million and a median of $347.2 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments tumbled 57.97% in 2023, then surged 128.93% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $461.3 million in 2022, then slumped by 44.75% to $254.9 million in 2023, then soared by 77.97% to $453.6 million in 2024, then sank by 31.95% to $308.7 million in 2025, then grew by 24.48% to $384.2 million in 2026.
• Business Quant data shows SUPN's Cash & Current Investments at $384.2 million in Q1 2026, $308.7 million in Q4 2025, and $281.2 million in Q3 2025.